Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

4.77
+0.08201.75%
Volume:10.49K
Turnover:49.77K
Market Cap:124.13M
PE:-2.23
High:4.79
Open:4.74
Low:4.74
Close:4.69
52wk High:12.99
52wk Low:3.01
Shares:26.01M
Float Shares:9.16M
Volume Ratio:1.65
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1361
EPS(LYR):-3.2036
ROE:--
ROA:-634.99%
PB:-5.73
PE(LYR):-1.49

Loading ...

Neonc Technologies Reports Positive Topline Phase 2a Results for Intranasal Neo100 in Recurrent Idh1-Mutant High-Grade Glioma

THOMSON REUTERS
·
Aug 12

Neonc Technologies - Median Overall Survival Reported at 26.09 Months; 86.7% Alive at Six Months

THOMSON REUTERS
·
Aug 12

Neonc Technologies - Phase 2a Study Meets Primary Endpoint with Six-Month Pfs of 48.9%

THOMSON REUTERS
·
Aug 12

Neonc Technologies - to Request Type B FDA Meeting for Registrational Path

THOMSON REUTERS
·
Aug 12

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Aug 12

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

GlobeNewswire
·
Aug 10

NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate

Benzinga Earnings
·
Aug 10

Neonc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout

THOMSON REUTERS
·
Aug 10

Neonc Technologies - Q2 2026 Net Loss $14.20 Mln or $(0.58) Per Diluted Share

THOMSON REUTERS
·
Aug 10

Press Release: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout

Dow Jones
·
Aug 10

NeOnc Technologies Hosts Call on Phase 2a Topline Data for Intranasal Neo100 in Recurrent IDH1-Mutant Glioma

Reuters
·
Aug 10

NeOnc Technologies Appoints Accenture Strategy Executive Nasim Shomali to Board

Reuters
·
Jul 27

Neonc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

THOMSON REUTERS
·
Jul 27

Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

Dow Jones
·
Jul 27

Neonc Gets FDA Written Feedback Backing Neo212 CMC Plan, Flags Bioavailability Study for Tablet Switch

Reuters
·
Jul 15

Neonc Technologies - FDA Finds Neonc's Cmc Development Approach Reasonable with Conditions on Manufacturing Changes

THOMSON REUTERS
·
Jul 15

Neonc Receives FDA Written Feedback on Neo212 Cmc Development and Capsule-to-tablet Transition

THOMSON REUTERS
·
Jul 15

Neonc Technologies - Cancels July 9 FDA Meeting After Sufficient Written Responses

THOMSON REUTERS
·
Jul 15

Neonc Technologies - to Update Neo212 Development Plan After Incorporating FDA Feedback

THOMSON REUTERS
·
Jul 15

Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off

Simply Wall St.
·
Jul 15